Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban.

This study focuses on rapid assay for the therapeutic drug monitoring of edoxaban.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the clinical field. Edoxaban is a direct oral anticoagulant (DOAC) that has been recently indicated for the treatment of pulmonary embolism (PE) in SARS-CoV-2 infections. Due to its pharmacokinetic variability and a narrow therapeutic index, the safe administration of the drug requires its therapeutic drug monitoring (TDM) in patients receiving the treatment. In... Research Background and Significance Edoxaban is a direct oral anticoagulant (DOAC) widely used to prevent and treat thromboembolic disorders, including pulmonary embolism (PE), especially relevant in SARS-CoV-2 infected patients where coagulopathy is a serious concern. Due to its narrow therapeutic index and significant pharmacokinetic variability among individuals, precise therapeutic drug monitoring (TDM) is essential to balance efficacy and safety, minimizing risks such as bleeding or therapeutic failure. Traditional methods for quantifying edoxaban plasma levels are often time-consuming or lack sufficient sensitivity and specificity for routine clinical use. This study by Rashid et al. addresses these challenges by developing a rapid, reliable, and validated high-performance liquid chromatography (HPLC) method tailored for clinical TDM of edoxaban. The significance of this work lies in its potential to improve patient management by enabling timely and accurate dose adjustments, ultimately enhancing therapeutic outcomes in high-risk patients. Experimental Design and Methodology The study employed an HPLC-based analytical approach optimized for rapid quantification of edoxaban in biological matrices, specificall